35Pharma Inc. is a Canada-based, private clinical-stage biopharmaceutical company headquartered in Montreal, Quebec, specializing in the development of novel protein-based therapeutics targeting the TGF-beta superfamily, particularly Activin and GDF ligand traps.
The company's lead candidate, HS235, is a next-generation activin signaling inhibitor designed for enhanced selectivity to minimize risks like bleeding associated with BMP9/10 binding. HS235 has completed Phase I trials in healthy volunteers, demonstrating fat-selective weight loss, lean mass preservation, and improved insulin sensitivity. Proof-of-concept studies are initiating in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
In February 2026, GSK announced the acquisition of 35Pharma for $950 million in cash, recently completed, to accelerate HS235 development and expand its respiratory and immunology portfolio. An earlier-stage candidate, HS370, targets heart failure and obesity.
Also known as 35 Pharma.
None yet. When a new project in the record names 35Pharma as owner, partner or investor, it shows here.
Deal closed for biotech developing HS235, an activin‑receptor therapy for pulmonary hypertension; designed to cut bleeding risk and offer metabolic benefits. PoC trials in PAH and PH‑HFpEF planned.
